Dr. Greg Robertson serves as a member of TransMed7’s Clinical and Scientific Advisory Board.
Dr. Robertson is a cardiologist and vascular specialist at Emory University. He is board certified in cardiovascular diseases, interventional cardiology, vascular medicine and endovascular medicine.
Dr. Robertson practiced for 16 years with device entrepreneur Dr. John Simpson at Seqouia and Stanford University hospitals. Dr. Robertson became a well-known academic leader in Dr. Simpson’s invention of atherectomy-catheter based plaque removal and percutaneous suture based closure. At Stanford he was part of Dr. Paul Yock’s Bio-design program.
Dr. Robertson was with start-up Foxhollow Technology for four years, helping to spearhead its bio-design and to revolutionize the way that people with PAD are treated. Before joining the interventional faculty at Emory University, Dr. Robertson spent six months with global innovator Professor Horst Sievert in Frankfurt, Germany on the forefront of structural heart disease, carotid stenting, PEVAR and assisting in clinical new device research.
At Emory University, Dr. Robertson has practiced global endovascular medicine performing complex cardiac and vascular interventions and has helped to start a new Emory hospital, where he is now chief of cardiology and director of interventional cardiology.
For nearly 30 years, Dr. Robertson has been actively involved in start-up company investments. He is a member of the Bay Area Life Science Angels and BioPacific Venture groups. He’s been a consultant to developmental design, testing, and teaching of numerous endovascular devices, including John Simpson’s inventions through DVI, Lumend, Perclose, Foxhollow, and currently with Avinger Technologies. He has served on several start-up scientific advisory boards and on the board of a new cardiac hospital venture in Beijing.